Bal Pharma share news, announcements and annual reports
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Bal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, May 2006 on NSE
Last close ₹81.85down ₹2.76 (3.26%)BSE ₹81.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹84.61.
30 Oct: open ₹84.05, high ₹84.05, low ₹81.21
52-week range of traded prices to 30 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹130 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.08
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,401
Bal Pharma share news and announcements
549 announcements, routine notices left out, newest first. Page 7 of 11.
Aug 2019
13 Aug · Board meeting
Jul 2019
22 Jul · Updates
Jun 2019
29 Jun · Management
19 Jun · Related Party Transactions
May 2019
31 May · Results
30 May · Board meeting
Apr 2019
Mar 2019
Feb 2019
15 Feb · Updates
13 Feb · Board meeting
13 Feb · Results
Jan 2019
14 Jan · Board meeting
Dec 2018
14 Dec · Legal
Exchange has sought clarification from Bal Pharma Limited with respect to announcement dated 03-Dec-2018, regarding " Bal Pharma Limited has informed the Exchange regarding 'Commencement of commercial production.Disclosure as per Regulation 30 of SEBI(LODR) Regulations. With reference to the above, we would like to inform the exchange that after obtaining all the regulatory approvals, our bulk drugs manufacturing unit at Udaipur has commenced its commercial production of intermediates and Active Pharma Ingredients (API). The API products which of scheduled to be manufactured at this Unit were developed by our R&D facility at Bangalore and due to capacity constraints at our Bangalore facility they could not become commercially viable till now. This unit is expected to ease the capacity concerns of API's and intermediates and will cater to the North are Northeastern markets of the country and also overseas markets. To recapitulate, we have acquired 100% share holding and management control of Golden Drugs Pvt Ltd, Udaipur, Rajasthan, during March 2018, which is into manufacturing of API's and intermediates, Please take this intimation on record.'.". On basis of above the Company is required to clarify following: 1. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief). 2. Percentage of shareholding / control acquired and / or number of shares acquired; 3. Nature of consideration - whether cash consideration or share swap and details of the same; 4. Cost of acquisition or the price at which the shares are acquired; 5. Indicative time period for completion of the acquisition; 6. Brief details of any governmental or regulatory approvals required for the acquisition; 7. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); 8. Industry to which the entity being acquired belongs; 9. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; 10. Name of the target entity, details in brief such as size, turnover etc; The response of the Company is awaited.
Nov 2018
19 Nov · Results
14 Nov · Results
14 Nov · Board meeting
Oct 2018
Sep 2018
24 Sep · Meeting
Aug 2018
14 Aug · Updates
10 Aug · Board meeting
10 Aug · Results
Jul 2018
Jun 2018
May 2018
30 May · Legal
Exchange has sought clarification from Bal Pharma Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted -2. Financial results not signed by authorized signatory/ies -3. Consolidated Reconciliation of profit and loss not submitted -4. Consolidated Reconciliation of Equity not submitted. The response of the Company is awaited.30 May · Results
Apr 2018
Mar 2018
26 Mar · Legal
Exchange has sought clarification from Bal Pharma Limited with respect to announcement dated 23-Mar-2018, regarding 'Disclosure as per Regulation 30 of the SEBI (LODR) Regulations.'.". On basis of above the Company is required to clarify following: 1. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).2. Percentage of shareholding / control acquired and / or number of shares acquired;3. Nature of consideration - whether cash consideration or share swap and details of the same;4. Cost of acquisition or the price at which the shares are acquired;5. Indicative time period for completion of the acquisition;6. Brief details of any governmental or regulatory approvals required for the acquisition;7. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);8. Industry to which the entity being acquired belongs;9. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";10. Name of the target entity, details in brief such as size, turnover etc;The response of the Company is awaited.